Key executive appointment supports strategic operational delivery of the Company’s product and partnership programs
London, UK, 20 June 2023: Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that enable personalized dose optimization, today announced that it has appointed Kate Woolland as Chief Operating Officer. Kate joins CEO, Dr. Hakim Yadi PhD OBE, on the executive team to guide organizational and operational delivery of the Company’s lead programs, products and commercial partnerships.
Kate’s appointment follows Closed Loop Medicine’s recent announcement of a co-development partnership deal with Pharmanovia, a global lifecycle management healthcare company, for drug plus software product solutions for the treatment of hypertension (1). Bringing extensive strategic business experience, including over 13 years in healthcare, Kate strengthens the executive team and supports the Company as it continues to scale commercial development. As COO, she will play a pivotal role in leading collaboration across the multi-disciplinary team whilst working closely with current and future commercial partners to drive delivery of Closed Loop Medicine’s products to market.
In her previous role, Kate was Chief Delivery Officer at ieso Digital Health, where she led product, design, clinical trial operations, commercial, regulatory and program management functions. During that time, Kate secured ieso’s first commercial partnerships and launched its first medical device; demonstrating capability that helped secure $53m Series B investment. Prior to this, Kate was a Partner for PA Consulting, during which time she supported the development of numerous commercial partnerships and built a healthcare system transformation consulting business worth over £10m p.a. She holds a Masters in Mathematics from The University of Manchester.
Kate Woolland, COO of Closed Loop Medicine, added: “I am thrilled to join the Closed Loop Medicine team at such an exciting stage. Leveraging the capabilities of our incredible technologies to revolutionize the dosing of medicines has the potential to help patients and healthcare professionals better manage health conditions, improve quality of life and health outcomes for millions of people. I am delighted to have the opportunity to play a part in such ground-breaking work.”
Dr. Hakim Yadi PhD OBE, CEO & Co-Founder of Closed Loop Medicine, commented: “As Chief Operating Officer, Kate brings a wealth of experience in optimizing and improving health systems and helping scale next generation digitally delivered health services from her time at ieso. We are on a mission to provide the right dose of medicine to patients and are excited to have Kate join us on this journey, helping build and develop our team dedicated to dose optimization and combination products.”
About Closed Loop Medicine
Closed Loop Medicine is a TechBio company developing combination prescription drug plus software products, with the aim of redefining precision medicine. The Company’s proprietary technology platform facilitates personalized drug dosing optimization, through integration of drugs and software with patient-led digital experiences and closed loop models of care. This approach has the potential to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases.
Founded at the Babraham Institute in Cambridge, UK in 2017, and now based in London, UK, Closed Loop Medicine’s investors include Ananda Impact Ventures, BGF, LifeArc, Longwall, Meltwind, IQ Capital, Downing Ventures and Cambridge Angels.
To learn more about Closed Loop Medicine and its mission to redefine personalized medicine, please visit: www.closedloopmedicine.com